A phase 2 study presented at #SOHO2026 evaluated frontline low-dose nivolumab (40 mg) + AVD for #HodgkinLymphoma:

🔹 95.8% ORR after 2 cycles
🔹 86.7% ORR after 6 cycles
🔹 75% total drug cost reduction vs standard dose

🩸Read more: https://bit.ly/4yjkaZC

Must Read #PediatricBloodandCancer: #Survival by Race and Ethnicity in Children and #AYA With Relapsed/Refractory #HodgkinLymphoma: A Pooled Analysis of Children's #Oncology Group Trials. #MallorieHeneghan #PHODocs #PedsHemeOnc onlinelibrary.wiley.com/doi/10.1002/...